Best practice

GSK reinforces access to a paediatric HIV medicine

GSK expands access to dolutegravir via 15 voluntary licences.

Explore further

How we measure

How we measure

The Index evaluates pharmaceutical companies in areas where they have the biggest potential and responsibility to make change, such as R&D and pricing. Find out more about the analytical framework and areas of evaluation.

Get in touch

Back to top |